All In Biotech

Drug Trial Radar · NCT05862285

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jun 1, 2023

Primary completion

Mar 1, 2033

Study completion Mar 1, 2033

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
May 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP\[s\]) monotherapy or Roche IMP(s) combined with other agent(s) or comparator agent(s) for eligible participants with cancer who are still on study treatment at the time of roll-over from the parent study and who do not have access to the study treatment locally.

Conditions

  • Cancer

Interventions

  • IpatasertibDrug

    Ipatasertib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.

  • TiragolumabDrug

    Tiragolumab in combination with atezolizumab will be administered at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.

  • AtezolizumabDrug

    Atezolizumab will be administered as a monotherapy and in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants' discontinuation from the parent study.

  • Tiragolumab and AtezolizumabDrug

    Tiragolumab and Atezolizumab in fixed dose combination administered intravenously (IV) at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.

  • BevacizumabDrug

    Bevacizumab will be administered as a monotherapy or in combination with atezolizumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.

  • EntrectinibDrug

    Entrectinib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.

  • InavolisibDrug

    Inavolisib will be administered as a monotherapy or in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.

  • DivarasibDrug

    Divarasib will be administered as a monotherapy or in combination with atezolizumab or bevacizumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.

  • GiredestrantDrug

    Giredestrant will be administered as a monotherapy or in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Continued Access to Roche IMP(s)-Based Therapy and/or Comparator Agent(s)Time frame: Up to approximately 10 years
  2. Number and Severity of Participants With Selected Adverse Events Assessed as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0Time frame: Up to approximately 10 years

Locations

85 sites in 15 countries. Site status is shown where the registry gives one.

  • GHdC Site Les Viviers

    Charleroi, Belgium · Completed

  • AZ Groeninge

    Kortrijk, Belgium · Active not recruiting

  • UZ Leuven Gasthuisberg

    Leuven, Belgium · Completed

  • UZ Leuven Gasthuisberg

    Leuven, Belgium · Active not recruiting

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada · Recruiting

  • Beijing Cancer Hospital

    Beijing, China · Recruiting

  • the First Hospital of Jilin University

    Changchun, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, China · Recruiting

  • Cancer Center of Guangzhou Medical University

    Guangzhou, China · Recruiting

  • Nanfang Hospital, Southern Medical University

    Guangzhou, China · Recruiting

  • Zhejiang People's Hospital

    Hangzhou, China · Recruiting

  • Sir Run Run Shaw Hospital Zhejiang University

    Hangzhou, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, China · Recruiting

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, China · Recruiting

  • Meizhou People's Hospital

    Meizhou, China · Recruiting

  • The 1st Affiliated Hospital of Nanchang Unversity

    Nanchang, China · Recruiting

  • Jiangsu Province Hospital of Chinese Medicine

    Nanjing, China · Recruiting

  • Shanghai Chest Hospital

    Shanghai, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, China · Recruiting

  • Shanghai Geriatric Medical Center

    Shanghai, China · Recruiting

  • Tianjin Cancer Hospital

    Tianjin, China · Recruiting

  • First Affiliated Hospital of Medical College of Xi'an Jiaotong University

    Xi'an, China · Recruiting

  • Xi'an International Medical Center Hospital

    Xi'an, China · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, China · Recruiting

  • The First Affiliated Hospital of Xinxiang Medical University

    Xinxiang, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, China · Recruiting

  • Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology

    Wuhan, Hubei, China · Recruiting

  • First Affiliated Hospital of Medical College of Xi'an Jiaotong University

    XI 'an City, Shaanxi Province, Shaanxi, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • Clinica CIMCA

    San José, Costa Rica · Active not recruiting

  • ICIMED Instituto de Investigación en Ciencias Médicas

    San José, Costa Rica · Active not recruiting

  • Institut Bergonie

    Bordeaux, France · Recruiting

  • Centre Francois Baclesse

    Caen, France · Recruiting

  • Institut de Cancérologie de Bourgogne

    Dijon, France · Recruiting

  • Centre Leon Berard

    Lyon, France · Recruiting

  • Hopital de la Timone

    Marseille, France · Recruiting

  • Centre Régional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque

    Montpellier, France · Recruiting

  • CHU de Nantes - Hotel Dieu

    Nantes, France · Recruiting

  • Institut de cancerologie du Gard

    Nîmes, France · Completed

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.